Locations
Boston, MA, USA · Boulder, CO, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2019
AOA Dx is a pioneering biotechnology company focused on early cancer detection, particularly in women's health. Founded in 2020, the company has developed innovative technologies such as Glyco Locate™ and AKRIVIS GD™, which utilize tumor marker gangliosides for non-invasive early-stage ovarian cancer diagnostics. AOA Dx differentiates itself through its unique multi-omics platform and commitment to transforming women's health by commercializing groundbreaking medical technologies. With significant funding rounds and a growing team of experts, AOA Dx is positioned to make a substantial impact in the oncology market, aiming to improve patient outcomes and reduce mortality rates associated with ovarian cancer.
Something looks off?On-site & Remote